ATLANTA, Feb. 24, 2010 (GLOBE NEWSWIRE) -- OTC Stock Review announces it has initiated coverage of PuraMed BioScience (OTCBB:PMBS). PuraMed BioScience, based in Schofield, WI, develops and markets the LipiGesic brand of non-prescription medicinal and healthcare products, which are marketed directly to consumers through direct response television commercials and the eCommerce websites http://www.lipigesic.com and http://www.mymigrainegone.com.
On February 23, 2010, PMBS announced approval to run direct response television commercials featuring LipiGesic M on major cable networks. In our opinion, this is a tremendous development as PMBS expands its marketing efforts to include all major retail channels. In addition to LipiGesic M, which provides relief from migraine headaches, PMBS plans to launch LipiGesic H, for more prevalent tension headaches, and LipiGesic PM, a remedy for insomnia and other sleep disorders.
Product development and design packaging of all PuraMed products have been conducted by the Company's two principal officers, Russell Mitchell and James Higgins. Both men have extensive experience in new product development and marketing of non-prescription medical products and nutritional supplements.
Mr. Mitchell previously founded Mitchell Health Technologies, the master broker for the launch of Quigley Corporation's "Cold-Eeze" non-prescription treatment for common colds, which within 18 months exceeded $70 million in annual wholesale revenues. In our opinion, the long and successful professional involvement of the PMBS management team in its industry is a valuable asset to draw upon and one of the foremost reasons investors will want to own this stock.
The complete report is available at http://www.otcstockreview.com/Files/PMBS/PMBS_Review.pdf.
Additionally, more information on PuraMed BioScience is available at http://www.puramedbioscience.com.
NOTE: The purpose of this release is to introduce the reader to OTCStockReview.com and PuraMed BioScience. OTC Stock Review is not a Registered Investment Advisor or a Broker/Dealer. Information and opinions presented in this release are solely for informative purposes and not intended, nor should they be construed as, investment advice. This document contains information obtained from public sources about PuraMed BioScience, but does not contain all the relevant material information necessary to evaluate the company. This release is not to be considered an offer to buy, sell, hold, and/or otherwise trade in the securities of PuraMed BioScience, as profiled. OTC Stock Review has been compensated six thousand two hundred and fifty dollars to perform investor relations services for PuraMed BioScience. Carefully review profiled companies with your investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Readers are encouraged to obtain copies of the profiled Company's periodic reports filed with United States Securities and Exchange Commission, which are generally available at http://www.sec.gov. You can view our complete disclaimer at http://www.otcstockreview.com/disclaimer.htm.